Age-associated functional decline in tissue-specific adult stem cells is thought to contribute to the loss of tissue homeostasis and age-related pathophysiology. Aging in the hematopoietic system is associated with diminished regenerative potential, reduced immune competence, and predisposition to myelogenous disease, including an elevated incidence of myelodysplastic syndrome (MDS) and myeloid leukemia (Rossi et al., 2008) . Evidence suggests that aging of hematopoietic stem cells (HSCs) may be central to the onset of these pathophysiologies. The functional potential of HSCs changes with age with old HSCs exhibiting a reduced capacity to regenerate the hematopoietic system and an altered lineage potential wherein lymphoid differentiation diminishes in favor of myeloid differentiation through a number of cell-autonomous mechanisms, including DNA-damage accumulation (Rossi et al., 2007; Rü be et al., 2011) , clonal dominance of myeloidbiased HSCs (Beerman et al., 2010; Morita et al., 2010) , and alterations in lineage specification programs (Chambers et al., 2007; Rossi et al., 2005) . To date, a direct connection has not been made between the accrual of DNA damage in HSCs and their differentiation potential. That DNA damage in stem cells might influence differentiation potential was first demonstrated in melanocyte stem cells (MSCs), in which irreparable genotoxic stress induces premature differentiation into mature melanocytes (Inomata et al., 2009) . Extending this paradigm to the hematopoietic system, Wang et al. (2012) now identify a surprising mechanistic link between the DNA-damage response (DDR) in HSCs and their differentiation potential that is mediated by Batf (basic leucine zipper transcription factor, ATFlike).
Batf belongs to the AP-1 transcription factor superfamily and induces differentiation in cells of lymphoid and myeloid lineages in a Stat3-dependent manner following cytokine stimulation (Liao et al., 2011) . However, a role in regulating the functional potential of primitive hematopoietic stem and progenitor cells (HSPCs) had not been shown. Using an in vivo small hairpin RNA-mediated knockdown to identify genes that regulate HSCs in a setting of telomerase deficiency (leading to induction of DDR), Wang et al. identify four candidate genes. Of these, only Batf specifically exerts its effects in the setting of telomere attrition. Moreover, Batf is the most enriched target of their screen. Based on these findings, the authors hypothesize that Batf might be involved in restricting the self-renewal of HSCs in the telomerase-deficient background.
This view is then supported by experiments in which serial transplantation of telomerase-deficient HSCs selects for Batf knockdown, though interestingly, loss of Batf does not appear to affect wild-type HSCs. Experiments with irradiated Batf-deficient mice reveal that loss of Batf confers a selective advantage to HSCs due to an attenuation of the DDR. Strikingly, HSCs lacking Batf exhibit evidence of persistent DNA damage, consistent with what has been reported in HSCs isolated from old mice and elderly humans (Rossi et al., 2007; Rü be et al., 2011) . Indeed, when the authors examined aged mice, they found that both Batf mRNA and protein are increased in HSCs. These results are consistent with age-associated DNA-damage accumulation in HSCs (Rossi et al., 2007; Rü be et al., 2011) , thus leading to an increase in Batf.
In exploring the relationship between Batf and p53, a central mediator of the DNA-damage response, the authors find that Batf is required for p53 activation and induction of p53-target genes in response to DNA damage. This helps explain why Batf-deficient HSCs exhibit improved maintenance and function even in the presence of DNA damage. Furthermore, the current study integrates the cytokine signaling/microenvironmental cues to DNA-damage-induced loss of stem cell function by demonstrating that DNA-damage-associated Batf induction requires G-CSF/Stat3 signaling.
Diminished adaptive immune competence due to deficiencies in B and T lymphocytes is perhaps the most penetrant attribute of the aged hematopoietic system. Although loss of lymphoid potential is a cell-autonomous attribute of HSC aging, the precise mechanisms underlying this have remained elusive. Recently, however, distinct HSC subsets have been identified that shed some light on this issue. Based on differential expression of CD150, two studies recently reported that long-term repopulating HSCs could be subfractionated into two functionally distinct subsets, one of which is more predisposed to lymphoid differentiation (CD150 lo ), whereas the Cell 148, March 2, 2012 ª2012 Elsevier Inc. 847 other is more predisposed to myeloid differentiation (CD150 hi ) (Beerman et al., 2010; Morita et al., 2010) . With advanced age, the CD150 hi myeloid-biased HSCs predominate in the HSC pool, which in part helps to explain the age-associated loss of lymphoid potential. The study by Wang et al. now provides important mechanistic insights that may explain the selective loss of HSC lymphoid potential during aging. Using an elegant interleukin-7 receptor-reporter system, the researchers find that lymphoid-biased CD150 lo HSCs are induced to lymphoid differentiation in response to DNA damage through upregulation of lymphoid specification genes (Figure 1) . By committing to differentiate, the lymphoid-biased
HSCs forgo self-renewal. Downstream of HSCs, the common lymphoid progenitors (CLPs) may also be regulated by Batf, which is highly expressed in these cells and increases with age. A comparative analysis of Batf-induced DNA-damage responses in downstream hematopoietic progenitors may shed light on the differences in lymphoid and myeloid potential that underlie hematopoietic aging. We postulate that age-associated Batf induction of a p53-dependent DNA-damage response in CLPs could be robust and may ultimately underlie the loss of lymphoid compartment during aging. In summary, the age-associated increase in Batf could represent a fail-safe mechanism to restrict the propagation and expansion of defective HSC clones through the induction of differentiation to the lymphoid lineage. Moreover, with the identification of Batf as an inducer of a p53-dependent DNA-damage response, therapies aimed at manipulating Batf levels or activity could play a role in disease management or cancer therapy. 
